Business Description
![Xeris Biopharma Holdings Inc Xeris Biopharma Holdings Inc logo](https://static.gurufocus.com/logos/0C0000BGRN.png?14)
Xeris Biopharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US98422L1070
Share Class Description:
XERS: Ordinary SharesDescription
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | -0.03 | |||||
Debt-to-Equity | -29.28 | |||||
Debt-to-EBITDA | -10.87 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -1.49 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 35.5 | |||||
3-Year EBITDA Growth Rate | 54.7 | |||||
3-Year EPS without NRI Growth Rate | 39.8 | |||||
3-Year FCF Growth Rate | 42.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 17.08 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.61 | |||||
9-Day RSI | 63.82 | |||||
14-Day RSI | 62.69 | |||||
6-1 Month Momentum % | -11.65 | |||||
12-1 Month Momentum % | -9.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 1.81 | |||||
Cash Ratio | 1.2 | |||||
Days Inventory | 457.07 | |||||
Days Sales Outstanding | 78.24 | |||||
Days Payable | 135.4 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.3 | |||||
Shareholder Yield % | -17.42 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 82.9 | |||||
Operating Margin % | -26.25 | |||||
Net Margin % | -37.58 | |||||
FCF Margin % | -25.31 | |||||
ROE % | -1019.2 | |||||
ROA % | -19.67 | |||||
ROIC % | -20.86 | |||||
ROC (Joel Greenblatt) % | -123.92 | |||||
ROCE % | -15.53 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.07 | |||||
EV-to-EBIT | -14.75 | |||||
EV-to-EBITDA | -22.62 | |||||
EV-to-Revenue | 3.26 | |||||
EV-to-Forward-Revenue | 2.98 | |||||
EV-to-FCF | -12.9 | |||||
Earnings Yield (Greenblatt) % | -6.78 | |||||
FCF Yield % | -11.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XERS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xeris Biopharma Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 171.356 | ||
EPS (TTM) ($) | -0.46 | ||
Beta | 1.02 | ||
Volatility % | 65.21 | ||
14-Day RSI | 62.69 | ||
14-Day ATR ($) | 0.127358 | ||
20-Day SMA ($) | 2.30425 | ||
12-1 Month Momentum % | -9.84 | ||
52-Week Range ($) | 1.46 - 3.26 | ||
Shares Outstanding (Mil) | 148.26 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xeris Biopharma Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xeris Biopharma Holdings Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Xeris Biopharma Holdings Inc Frequently Asked Questions
What is Xeris Biopharma Holdings Inc(XERS)'s stock price today?
The current price of XERS is $2.60. The 52 week high of XERS is $3.26 and 52 week low is $1.46.
When is next earnings date of Xeris Biopharma Holdings Inc(XERS)?
The next earnings date of Xeris Biopharma Holdings Inc(XERS) is 2024-08-08 Est..
Does Xeris Biopharma Holdings Inc(XERS) pay dividends? If so, how much?
Xeris Biopharma Holdings Inc(XERS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |